JP2003520605A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520605A5 JP2003520605A5 JP2001554420A JP2001554420A JP2003520605A5 JP 2003520605 A5 JP2003520605 A5 JP 2003520605A5 JP 2001554420 A JP2001554420 A JP 2001554420A JP 2001554420 A JP2001554420 A JP 2001554420A JP 2003520605 A5 JP2003520605 A5 JP 2003520605A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- protein
- seq
- fragment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002157 polynucleotide Substances 0.000 description 34
- 108091033319 polynucleotide Proteins 0.000 description 29
- 102000040430 polynucleotide Human genes 0.000 description 29
- 238000000034 method Methods 0.000 description 18
- 239000012634 fragment Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17856000P | 2000-01-26 | 2000-01-26 | |
| US60/178,560 | 2000-01-26 | ||
| PCT/US2001/002651 WO2001055391A2 (en) | 2000-01-26 | 2001-01-26 | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006162937A Division JP5501550B2 (ja) | 2000-01-26 | 2006-06-12 | ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520605A JP2003520605A (ja) | 2003-07-08 |
| JP2003520605A5 true JP2003520605A5 (https=) | 2006-07-27 |
| JP3946044B2 JP3946044B2 (ja) | 2007-07-18 |
Family
ID=22653018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001554420A Expired - Fee Related JP3946044B2 (ja) | 2000-01-26 | 2001-01-26 | ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質 |
| JP2006162937A Expired - Fee Related JP5501550B2 (ja) | 2000-01-26 | 2006-06-12 | ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006162937A Expired - Fee Related JP5501550B2 (ja) | 2000-01-26 | 2006-06-12 | ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7510855B2 (https=) |
| EP (2) | EP1250434B1 (https=) |
| JP (2) | JP3946044B2 (https=) |
| AT (2) | ATE392474T1 (https=) |
| AU (2) | AU3797301A (https=) |
| CA (1) | CA2398064C (https=) |
| CY (1) | CY1111522T1 (https=) |
| DE (2) | DE60133627T2 (https=) |
| DK (1) | DK1967586T3 (https=) |
| ES (2) | ES2304126T3 (https=) |
| IL (2) | IL150873A0 (https=) |
| WO (1) | WO2001055391A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1250434B1 (en) * | 2000-01-26 | 2008-04-16 | Agensys, Inc. | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| CA2822302A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Methods of impairing osteoclast differentiation |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| US9493562B2 (en) | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| SG11201501646PA (en) * | 2012-09-07 | 2015-04-29 | Agency Science Tech & Res | Peptides and their uses |
| WO2022013154A1 (en) * | 2020-07-14 | 2022-01-20 | Myneo Nv | Method, system and computer program product for determining presentation likelihoods of neoantigens |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| TR199902053T2 (xx) * | 1997-02-25 | 2000-04-21 | Corixa Corporation | Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar. |
| EP0973898A2 (en) | 1997-04-10 | 2000-01-26 | Genetics Institute, Inc. | SECRETED EXPRESSED SEQUENCE TAGS (sESTs) |
| EP1053319A2 (en) | 1998-01-28 | 2000-11-22 | Chiron Corporation | Human genes and gene expression products ii |
| US6013450A (en) | 1998-02-20 | 2000-01-11 | Incyte Pharmaceuticals, Inc. | CAF1-related protein |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| WO2001051628A2 (en) | 2000-01-14 | 2001-07-19 | Millennium Pharmaceuticals, Inc. | Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1250434B1 (en) * | 2000-01-26 | 2008-04-16 | Agensys, Inc. | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| CA2395872A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001249642A1 (en) | 2000-04-06 | 2001-10-23 | Genetics Institute, Llc | Polynucleotides encoding novel secreted proteins |
| CN1328147A (zh) | 2000-06-12 | 2001-12-26 | 上海博德基因开发有限公司 | 一种新的多肽——人磷脂酶49.06和编码这种多肽的多核苷酸 |
| US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
| AU2002210791A1 (en) | 2000-07-28 | 2002-02-13 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
| AU2001290548A1 (en) | 2000-09-11 | 2002-03-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| EP1325120A4 (en) | 2000-10-12 | 2005-05-25 | Nuvelo Inc | NUCLEIC ACIDS AND POLYPEPTIDES |
| AU2002253878A1 (en) | 2001-01-25 | 2002-08-06 | Gene Logic, Inc. | Gene expression profiles in breast tissue |
-
2001
- 2001-01-26 EP EP01910358A patent/EP1250434B1/en not_active Expired - Lifetime
- 2001-01-26 ES ES01910358T patent/ES2304126T3/es not_active Expired - Lifetime
- 2001-01-26 JP JP2001554420A patent/JP3946044B2/ja not_active Expired - Fee Related
- 2001-01-26 EP EP08154530A patent/EP1967586B1/en not_active Expired - Lifetime
- 2001-01-26 AU AU3797301A patent/AU3797301A/xx active Pending
- 2001-01-26 CA CA2398064A patent/CA2398064C/en not_active Expired - Fee Related
- 2001-01-26 AU AU2001237973A patent/AU2001237973B2/en not_active Ceased
- 2001-01-26 US US09/771,312 patent/US7510855B2/en not_active Expired - Fee Related
- 2001-01-26 DK DK08154530.3T patent/DK1967586T3/da active
- 2001-01-26 WO PCT/US2001/002651 patent/WO2001055391A2/en not_active Ceased
- 2001-01-26 DE DE60133627T patent/DE60133627T2/de not_active Expired - Lifetime
- 2001-01-26 AT AT01910358T patent/ATE392474T1/de active
- 2001-01-26 IL IL15087301A patent/IL150873A0/xx unknown
- 2001-01-26 ES ES08154530T patent/ES2360155T3/es not_active Expired - Lifetime
- 2001-01-26 DE DE60144204T patent/DE60144204D1/de not_active Expired - Lifetime
- 2001-01-26 AT AT08154530T patent/ATE501255T1/de active
-
2002
- 2002-07-23 IL IL150873A patent/IL150873A/en not_active IP Right Cessation
-
2006
- 2006-06-12 JP JP2006162937A patent/JP5501550B2/ja not_active Expired - Fee Related
- 2006-11-07 US US11/594,275 patent/US7582448B2/en not_active Expired - Fee Related
-
2008
- 2008-11-26 US US12/324,707 patent/US8013126B2/en not_active Expired - Fee Related
-
2011
- 2011-06-03 CY CY20111100538T patent/CY1111522T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | PSCA is a target of chimeric antigen receptor T cells in gastric cancer | |
| CN107686520A (zh) | 抗pd‑l1纳米抗体及其应用 | |
| EP3792280A2 (en) | Anti-blys antibody | |
| UA104130C2 (uk) | Антитіло, що специфічно зв'язується з il-4 і іl-13 та спосіб лікування астми у ссавця за допомогою такого антитіла | |
| CN114195894B (zh) | 一种靶向4-1bb的抗体及其应用 | |
| CN108949692A (zh) | 表达cxcl10和ccl21趋化因子靶向嵌合抗原受体t淋巴细胞的构建方法及应用 | |
| JP2007525183A5 (https=) | ||
| EP2596023A2 (en) | Compositions and methods featuring il-6 and il-21 antagonists | |
| WO2023125842A1 (zh) | 一种新型upar单域抗体的开发 | |
| EP0851030B9 (en) | PROTEIN SPECIFIC TO HUMAN Th2, GENE (B19) ENCODING THE SAME, AND TRANSFORMANT, RECOMBINANT VECTOR AND MONOCLONAL ANTIBODY RELATING THERETO | |
| EP1536006A1 (en) | Cancer antigens and utilization thereof | |
| CN118290584A (zh) | 一种包括nk细胞的药物组合物及其在制备治疗肿瘤药物中的应用 | |
| AU2019354395A1 (en) | Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors | |
| EP2984108A1 (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| JP2003520605A5 (https=) | ||
| CN114573709A (zh) | 携带趋化因子受体且靶向msln抗原的car t免疫细胞的制备及其用途 | |
| WO2006072954A2 (en) | Novel il-6 polynucleotides encoding variant il-6 polypeptides and methods using same | |
| KR20100034720A (ko) | 피에이유에프(ｐａｕｆ) 특이적인 인간 단일클론항체, 이를 포함하는 암 치료용 조성물, 이를 이용하는 암의 진단방법 | |
| CN118546246A (zh) | 特异性结合il-8的抗体、抗体片段及其用途 | |
| CN102181400A (zh) | 杂交瘤细胞株及抗hcclm-6细胞分泌蛋白单克隆抗体 | |
| US20080248011A1 (en) | Methods for Isolating Monocytes | |
| CN100491527C (zh) | 特征在于检测g-csf外显子3缺失的癌症诊断方法 | |
| CN116444672A (zh) | 人表皮生长因子3的抗体、其制备方法及其应用 | |
| CN108060136A (zh) | 一种用于治疗aml的嵌合抗原受体t细胞、制备方法及应用 | |
| CN113956359A (zh) | 一种抗体及其在抗肿瘤中的应用 |